Fri.Aug 02, 2024

article thumbnail

Opinion: The coronavirus lab leak hypothesis is damaging science

STAT

Where and when the Covid-19 pandemic began — in Wuhan, China in late 2019 — is well known. How it began is a matter of heated controversy. There are two competing hypotheses, one of which is hindering the process of scientific discovery and could hold back the development of vaccines and other antiviral agents in the U.S. The zoonosis hypothesis proposes that SARS-CoV-2, the virus that causes Covid-19, was naturally transmitted from an animal to one or more humans in a so-called we

Vaccines 363
article thumbnail

What pharma has learned from AI

PharmaVoice

As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.

279
279
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Weight loss drugs without a prescription? Study warns it’s a ‘very risky business’

STAT

In the face of ongoing shortages of the obesity and diabetes medications known as GLP-1s, patients have resorted to a wide array of sources for the drugs, including medical spas and telehealth sites that prescribe compounded versions of the drugs. But a new paper published in JAMA Network Open highlights one of the riskiest sources of non-branded drugs: illegal online pharmacies that bypass prescription entirely.

article thumbnail

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer

BioPharma Dive

Adaptimmune’s Tecelra is the first TCR cell therapy to reach market and, at $727,000, is also the priciest cellular medicine for cancer in the U.S.

120
120
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: UnitedHealth and HCA clash over hospital chain’s rates in ‘battle of the giants’

STAT

Contract disputes between hospitals and health plans have become routine, but they tend to be local , affecting a handful of hospitals and the people in the surrounding communities. This latest one is different. It involves the country’s biggest private health insurer, UnitedHealthcare, and its biggest hospital chain, HCA Healthcare. If they can’t strike a deal on prices by Sept. 1, 38 hospitals and their affiliated physician groups and surgery centers across four states — T

Hospitals 357
article thumbnail

Building a future-ready digital workforce in pharma

pharmaphorum

Discover how digital transformation is reshaping the pharmaceutical industry and learn how to prepare your workforce for the future with this guide on building a future-ready digital workforce in pharma.

111
111

More Trending

article thumbnail

Researchers reveal CAR-enhancer therapy could help overcome cancer relapse

Pharma Times

Cancer is estimated to affect more than three million people living in the UK, according to Macmillan Cancer Support

126
126
article thumbnail

Opinion: ACL tears in women: Too many injuries and too little research

STAT

Some of the world’s finest athletes were sidelined by a torn anterior cruciate ligament (the ligament that helps stabilize the knee joint) long before the torch was lit for the Paris Olympics. The list of women competitors with ACL tears is stunning. Basketball player Cameron Brink , rugby medalist Shiray Kaka, gymnast Asia D’Amato, and several other athletes will not be competing because of this all-too-common, season-ending, and potentially career-ruining injury.

322
322
article thumbnail

Lilly gets first heart outcomes readout with tirzepatide

pharmaphorum

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on cardiovascular outcomes with the drug.

113
113
article thumbnail

STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer

STAT

LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a rare cancer that arises in the body’s soft tissues, extending the power of immunotherapies to difficult-to-reach sarcomas.   The medicine, called Tecelra and developed by Adaptimmune Therapeutics, is what’s known as a T cell receptor therapy.

302
302
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

FDA approves innovative engineered cell therapy

European Pharmaceutical Review

For the first time in over a decade, there is a new treatment option for patients with synovial sarcoma, a rare soft tissue cancer. The US Food and Drug Administration (FDA) has granted accelerated approval for the cell therapy TECELRA ® (afamitresgene autoleucel) to treat adults with unresectable or metastatic forms of the disease. Adaptimmune Therapeutics highlighted that TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy.

article thumbnail

Opinion: Address liquid biopsy disparities today to ensure equity in outcomes tomorrow

STAT

The promise of scientific and medical innovation often comes with a downside: improvements in care benefit some people, but not all. Without concerted effort, that is exactly what could happen with liquid biopsy — an evolving technology aimed at improving cancer care using just a few milliliters of blood or other body fluids. Liquid biopsy technologies are maturing at a rapid pace.

295
295
article thumbnail

Otsuka Pharmaceutical to Purchase Jnana Therapeutics

Pharmaceutical Commerce

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.

105
105
article thumbnail

STAT+: 23andMe board rejects co-founder Anne Wojcicki’s offer to take company private

STAT

A special committee of the board of directors of 23andMe rejected an offer from the company’s co-founder and CEO, Anne Wojcicki, to take the company private. In a letter made public Friday, the board said that Wojcicki’s proposal failed to offer a premium to 23andMe’s current stock price, did not have committed financing from other investors, and came with other conditions it rejected.

288
288
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

RPS concern over 'potential criminalisation' in supplying puberty blockers

The Pharmacist

The Royal Pharmaceutical Society (RPS) has expressed concern over the potential criminalisation of pharmacists who supply puberty blockers, following a High Court ruling earlier this week upholding an emergency prohibition order on the medicines. The legislation – brought in by former health secretary Victoria Atkins in May – makes it a criminal offence to supply […] The post RPS concern over 'potential criminalisation' in supplying puberty blockers appeared first on The Pharmaci

94
article thumbnail

Moderna is still in a Covid hangover

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning and happy Friday. We discuss a new innovative immunotherapy, and we take a look at some of the earnings highlights yesterday.

article thumbnail

Closed and Collaborative: Mergers, acquisitions, and partnerships in June 2024

pharmaphorum

Explore the latest mergers, acquisitions, and partnerships in June 2024 involving LucidHealth, Syncona, Spur Therapeutics and more. Stay updated on the business collaborations shaping the industry.

101
101
article thumbnail

STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more

STAT

Good morning, and happy Friday. This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalot campus. As you may know from my past entries, I’m no coffee drinker, but here are some newsy items to help wake you up and kick-start your weekend. … The FDA has approved a cutting-edge treatment for a rare soft tissue cancer, STAT tells us.

article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Study reveals non-statin cholesterol drugs could reduce liver cancer risk

Pharma Times

The third leading cause of cancer mortality accounts for over 700,000 deaths every year

119
119
article thumbnail

Rejuvenate Biomed and SAS unveil AI tool to accelerate age-related drug development

Outsourcing Pharma

Rejuvenate Biomed and SAS have announced a creative partnership aimed at making big changes to drug discovery through the development of a user-friendly, AI-powered tool.

article thumbnail

GSK bags sought-after Jemperli okay in endometrial cancer

pharmaphorum

FDA clears GSK's Jemperli as first-line therapy for all endometrial cancer patients, seen as key to driving sales above the $1bn threshold

98
article thumbnail

How CDMOs can optimize operations and balance costs ahead of the 2032 BioSecure Act

Outsourcing Pharma

As the BioSecure Act approaches its 2032 implementation, Contract Development and Manufacturing Organizations (CDMOs) must prepare for significant industry shifts.

91
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Parexel releases 2023 Environmental, Social and Governance report

Express Pharma

Parexel, one of the world’s reportedly largest clinical research organisations (CROs) providing the full range of Phase I to IV clinical development services, announced the release of its 2023 Environmental, Social and Governance (“ESG”) Report. The ESG Report is part of Parexel’s annual commitment to disclose and communicate the progress of its sustainability priorities, underscoring the company’s core values of putting Patients First and delivering With Heart. “Our ESG p

article thumbnail

FDA clears Adaptimmune T-cell therapy for soft tissue cancer

pharmaphorum

FDA has approved Adaptimmune's Tecelra for synovial sarcoma, the first engineered T-cell therapy for solid tumours

104
104
article thumbnail

AbbVie acquires Cerevel Therapeutics for $8.7bn

Pharmaceutical Technology

AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.

98
article thumbnail

RPS concern over 'potential criminalisation' in prescribing puberty blockers

The Pharmacist

The Royal Pharmaceutical Society (RPS) has expressed concern over the potential criminalisation of pharmacists who prescribe puberty blockers, following a High Court ruling earlier this week upholding an emergency prohibition order on the medicines. The legislation – brought in by former health secretary Victoria Atkins in May – makes it a criminal offence to supply […] The post RPS concern over 'potential criminalisation' in prescribing puberty blockers appeared first on The Pha

79
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Artificial intelligence: The saviour of the pharmaceutical industry?

pharmaphorum

Discover how artificial intelligence is revolutionising the pharmaceutical industry and how it can potentially save time, resources, and lives. Learn more about the impact of AI on pharma and discussions at PING 2024.

83
article thumbnail

Finding the right balance for nutraceuticals

Express Pharma

Now that the Union Budget 2024-25 has been analysed, feted and criticised, it is time to remember that budgetary allocations are only a signal of the government’s intentions. The actions that follow and their implementation are more crucial. Given that we have around seven months before the next budget, it’s fair to say that most postbudget criticism could be aimed at setting the stage for February 2025’s Union Budget 2025-26.

article thumbnail

Abbvie acquires Cerevel Therapeutics

Pharmafile

Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric conditions such as schizophrenia, Parkinson’s disease and mood disorders. One example is emraclidine, a next-generation antipsychotic positive allosteric modulator (PAM) of the muscarinic M4 receptor, indicated for the treatment of schizophrenia.

72
article thumbnail

Unleashing the future of drug discovery with generative AI

Express Pharma

What edge does generative AI have over traditional methods? Before the pharmaceutical industry started warming up to generative AI, most operations and processes were conducted with minimal AI involvement. Even in cases where AI was incorporated, the algorithms were slow and inefficient, leading to increased ( 1 ) costs and operational complexities.

article thumbnail

These Concerns Are Keeping Your Pharmacy Team Awake at Night

The Script

Trying to understand your employees better? Rx relief explains a few potential concerns that could be keeping your team awake at night.